Marie-Laure Garrigues

BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development.

CDC Enterprises, Inc. designs, manufactures, and distributes patented HDPE ductwork products. It offers airtight, mildew, corrosion resistant, and thermal constructed ductwork products. The firm specializes in electrical instrumentation, controls and systems integration, for public works, utilities, private industry, and government organizations. It provides a wide range of services including pump efficiency monitoring, system diagnostics and troubleshooting, GPS mapping, robotic controls, panel design, and fabrication. The company was founded by Jon W. Jungers in April 2001 and is headquartered in Ringwood, IL.

eCential Robotics SAS is a French Grenoble-based company that specializes in surgical robotics. The company develops and markets a unique system that unifies 2D/3D robotic imaging and real-time navigation. With 80 patents and seven trademarks, it offers orthopedic and neurosurgeons cutting-edge technology to visualize their operations, particularly minimally invasive surgery. The eCential Robotics platform is a universal system open to all implants. The company designs and produces all its equipment in Grenoble, FR, including hardware and software. The company was founded in 2009 by Stéphane Lavallée and Markus Fleute.

Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.